<PubmedArticle xmlns:ns0="http://www.w3.org/1998/Math/MathML"><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39352566</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0305</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Molecular biotechnology</Title><ISOAbbreviation>Mol Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Glycoprofile Comparison of the SARS-CoV-2 Spike Proteins Expressed in CHO and HEK Cell Lines.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12033-024-01288-2</ELocationID><Abstract><AbstractText>Coronavirus SARS-CoV-2 spike protein remains a key focus of research due to a continued need for diagnostic and therapeutic tools to monitor and respond to new variants. Glycosylation of the spike protein is critical for the protein's functions in viral attachment and host cell entry. For scalable and cost-effective production of the spike protein, expression system-driven divergence in glycosylation patterns on recombinant spike proteins needs to be fully understood. This study assessed the N-glycosylation profiles of a full-length trimeric spike protein expressed in either Human Embryonic Kidney (HEK Expi293F) or Chinese Hamster Ovary (CHO-S) cells. Glycopeptide analysis was performed using a tandem mass spectrometry workflow and BioPharma <ns0:math> <ns0:msup><ns0:mrow><ns0:mtext>Finder</ns0:mtext></ns0:mrow> <ns0:mtext>TM</ns0:mtext></ns0:msup> </ns0:math> incorporating HEK and CHO glycan databases for protein characterisation. The results outline important differences in the variety and types of N-glycan generated by the two cell lines across the 22 known N-glycosylation sites of the spike protein. A notable increase in terminal sialylation, as well as the presence of the potentially immunogenic N-glycolylneuraminic acid at a functionally key N-glycosylation site, was observed in the CHO-S derived spike protein. With the potential for the relatively vast and more complex CHO glycan repertoire (182 glycans relative to 39 human glycans) to produce functional implications with CHO-S expressed spike protein, this study adds valuable knowledge to aid Quality by Design approaches and enable Multi Attribute Monitoring of specific N-glycosylation sites for proteoform analyses. This can further inform antigen development with future variants in order to devise updated diagnostic tests and therapeutic vaccine designs.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wright</LastName><ForeName>Helen L</ForeName><Initials>HL</Initials><Identifier Source="ORCID">0009-0007-4771-1618</Identifier><AffiliationInfo><Affiliation>School of Chemical, Materials and Biological Engineering, University of Sheffield, Mappin St., Sheffield, S1 3JD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Evans</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Chemical, Materials and Biological Engineering, University of Sheffield, Mappin St., Sheffield, S1 3JD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Philip J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>School of Biosciences, University of Sheffield, Western Bank, Sheffield, S10 2TN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>School of Chemical, Materials and Biological Engineering, University of Sheffield, Mappin St., Sheffield, S1 3JD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tee</LastName><ForeName>Kang Lan</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>School of Chemical, Materials and Biological Engineering, University of Sheffield, Mappin St., Sheffield, S1 3JD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Tuck Seng</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>School of Chemical, Materials and Biological Engineering, University of Sheffield, Mappin St., Sheffield, S1 3JD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickman</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>School of Chemical, Materials and Biological Engineering, University of Sheffield, Mappin St., Sheffield, S1 3JD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandhal</LastName><ForeName>Jagroop</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Chemical, Materials and Biological Engineering, University of Sheffield, Mappin St., Sheffield, S1 3JD, UK. j.pandhal@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BB/V509231/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BB/M012166/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Mol Biotechnol</MedlineTA><NlmUniqueID>9423533</NlmUniqueID><ISSNLinking>1073-6085</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">N-glycosylation</Keyword><Keyword MajorTopicYN="N">CHO Cells</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">HEK cells</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39352566</ArticleId><ArticleId IdType="doi">10.1007/s12033-024-01288-2</ArticleId><ArticleId IdType="pii">10.1007/s12033-024-01288-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Song, C., Li, Z., Li, C., Huang, M., Liu, J., Fang, Q., Cao, Z., Zhang, L., Gao, P., Nie, W., Luo, X., Kang, J., Xie, S., Lyu, J., &amp; Zhu, X. (2022). SARS-CoV-2: The monster causes COVID-19. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2022.835750</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.835750</ArticleId><ArticleId IdType="pubmed">36846550</ArticleId><ArticleId IdType="pmc">9831679</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, Q., &amp; Yan, J. (2021). SARS-CoV-2 virus: Vaccines in development. Fundamental Research, 1(2), 131–138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fmre.2021.01.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., &amp; Tan, W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine, 382(8), 727–733.</Citation><ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko, M., Marzi, A., &amp; Munster, V. (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nature Microbiology, 5, 562–569.</Citation><ArticleIdList><ArticleId IdType="pubmed">32094589</ArticleId><ArticleId IdType="pmc">7095430</ArticleId><ArticleId IdType="doi">10.1038/s41564-020-0688-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan, M., Liu, H., Wu, N. C., &amp; Wilson, I. A. (2021). Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochemical and Biophysical Research Communications, 538, 192–203.</Citation><ArticleIdList><ArticleId IdType="pubmed">33069360</ArticleId><ArticleId IdType="pmc">7547570</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, Y., Yang, C., Xu, X.-F., Xu, W., &amp; Liu, S.-W. (2020). Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacologica Sinica, 41, 1141–1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">32747721</ArticleId><ArticleId IdType="pmc">7396720</ArticleId><ArticleId IdType="doi">10.1038/s41401-020-0485-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S., &amp; Crispin, M. (2020). Site-specific glycan analysis of the SARS-CoV-2 spike. Science, 369(6501), 330–333.</Citation><ArticleIdList><ArticleId IdType="pubmed">32366695</ArticleId><ArticleId IdType="pmc">7199903</ArticleId><ArticleId IdType="doi">10.1126/science.abb9983</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian, W., Li, D., Zhang, N., Bai, G., Yuan, K., Xiao, H., Gao, F., Chen, Y., Wong, C. C., &amp; Gao, G. F. (2021). O-glycosylation pattern of the SARS-CoV-2 spike protein reveals an “O-Follow-N’’ rule. Cell Research, 31(10), 1123–1125.</Citation><ArticleIdList><ArticleId IdType="pubmed">34341488</ArticleId><ArticleId IdType="pmc">8326647</ArticleId><ArticleId IdType="doi">10.1038/s41422-021-00545-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., Zhao, W., Mao, Y., Chen, Y., Zheng, S., Cao, W., Zhu, J., Hu, L., Gong, M., Cheng, J., &amp; Yang, H. (2021). O-glycosylation landscapes of SARS-CoV-2 spike proteins. Frontiers in Chemistry, 9, 689521.</Citation><ArticleIdList><ArticleId IdType="pubmed">34552909</ArticleId><ArticleId IdType="pmc">8450404</ArticleId><ArticleId IdType="doi">10.3389/fchem.2021.689521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, P., Praissman, J. L., Grant, O. C., Cai, Y., Xiao, T., Rosenbalm, K. E., Aoki, K., Kellman, B. P., Bridger, R., Barouch, D. H., Brindley, M. A., Lewis, N. E., Tiemeyer, M., Chen, B., Woods, R. J., &amp; Wells, L. (2020). Virus–receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor. Cell Host and Microbe, 28(4), 586-601.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32841605</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2020.08.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici, M. A., Walls, A. C., Lang, Y., Wang, C., Li, Z., Koerhuis, D., Boons, G. J., Bosch, B. J., Rey, F. A., Groot, R. J., &amp; Veesler, D. (2019). Structural basis for human coronavirus attachment to sialic acid receptors. Nature Structural and Molecular Biology, 26(6), 481–489.</Citation><ArticleIdList><ArticleId IdType="pubmed">31160783</ArticleId><ArticleId IdType="doi">10.1038/s41594-019-0233-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson, B. (2020). Bioinformatics studies on a function of the SARS-CoV-2 spike glycoprotein as the binding of host sialic acid glycans. Computers in Biology and Medicine, 122, 103849.</Citation><ArticleIdList><ArticleId IdType="pubmed">32658736</ArticleId><ArticleId IdType="pmc">7278709</ArticleId><ArticleId IdType="doi">10.1016/j.compbiomed.2020.103849</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu, Y.-P., Frank, M., Mukherjee, D., Shchurik, V., Makarov, A., &amp; Mann, B. F. (2022). Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor-binding affinity. Glycobiology, 33(2), 126–137.</Citation><ArticleIdList><ArticleId IdType="pmc">9990995</ArticleId><ArticleId IdType="doi">10.1093/glycob/cwac077</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, L., McCord, K. A., Bui, D. T., Bouwman, K. M., Kitova, E. N., Elaish, M., Kumawat, D., Daskhan, G. C., Tomris, I., Han, L., Chopra, P., Yang, T.-J., Willows, S. D., Mason, A. L., Mahal, L. K., Lowary, T. L., West, L. J., Hsu, S.-T.D., Hobman, T., … Klassen, J. S. (2022). Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2. Nature Chemical Biology, 18(1), 81–90.</Citation></Reference><Reference><Citation>Baboo, S., Diedrich, J. K., Torres, J. L., Copps, J., Singh, B., Garrett, P. T., Ward, A. B., Paulson, J. C., &amp; Yates III, J. R. (2023). Evolving spike-protein N-glycosylation in SARS-CoV-2 variants. bioRxiv.</Citation></Reference><Reference><Citation>Sztain, T., Ahn, S.-H., Bogetti, A. T., Casalino, L., Goldsmith, J. A., Seitz, E., McCool, R. S., Kearns, F. L., Acosta-Reyes, F., Maji, S., Mashayekhi, G., McCammon, J. A., Ourmazd, A., Frank, J., McLellan, J. S., Chong, L. T., &amp; Amaro, R. E. (2021). A glycan gate controls opening of the SARS-CoV-2 spike protein. Nature Chemistry, 13, 963–968.</Citation><ArticleIdList><ArticleId IdType="pubmed">34413500</ArticleId><ArticleId IdType="pmc">8488004</ArticleId><ArticleId IdType="doi">10.1038/s41557-021-00758-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Casalino, L., Gaieb, Z., Goldsmith, J. A., Hjorth, C. K., Dommer, A. C., Harbison, A. M., Fogarty, C. A., Barros, E. P., Taylor, B. C., McLellan, J. S., Fadda, E., &amp; Amaro, R. E. (2020). Beyond shielding: The roles of glycans in the SARS-CoV-2 spike protein. ACS Central Science, 6(10), 1722–1734.</Citation><ArticleIdList><ArticleId IdType="pubmed">33140034</ArticleId><ArticleId IdType="pmc">7523240</ArticleId><ArticleId IdType="doi">10.1021/acscentsci.0c01056</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y., &amp; Butler, M. (2023). Quantitative profiling of N-glycosylation of SARS-CoV-2 spike protein variants. Glycobiology, 33(3), 188–202.</Citation><ArticleIdList><ArticleId IdType="pubmed">36723867</ArticleId><ArticleId IdType="pmc">10114651</ArticleId><ArticleId IdType="doi">10.1093/glycob/cwad007</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., Bermudez-Gonzalez, M., Kleiner, G., Aydillo, T., Lisa Miorin, D. S. F., Lugo, L. A., Kojic, E. M., Stoever, J., Liu, S. T. H., Cunningham-Rundles, C., … GarcÃ­a-Sastre, A., Caplivski, D., Cheng, A. C., Kedzierska, K., Vapalahti, O., Hepojoki, J. M., Simon, V., &amp; Krammer, F. (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature Medicine, 26, 1033–1036.</Citation></Reference><Reference><Citation>Cao, X. (2020). COVID-19: Immunopathology and its implications for therapy. Nature Reviews Immunology, 20, 269–270.</Citation><ArticleIdList><ArticleId IdType="pubmed">32273594</ArticleId><ArticleId IdType="pmc">7143200</ArticleId><ArticleId IdType="doi">10.1038/s41577-020-0308-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrens, G. M., Cossmann, A., Stankov, M. V., Nehlmeier, I., Kempf, A., Hoffmann, M., &amp; Pöhlmann, S. (2021). SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination. Lancet, 398(10305), 1041–1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">34416198</ArticleId><ArticleId IdType="pmc">8372487</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)01891-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, G. (2006). Biopharmaceutical benchmarks 2006. Nature Biotechnology, 24(7), 769–776.</Citation><ArticleIdList><ArticleId IdType="pubmed">16841057</ArticleId><ArticleId IdType="doi">10.1038/nbt0706-769</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh, G., &amp; Walsh, E. (2022). Biopharmaceutical benchmarks 2022. Nature Biotechnology, 40(12), 1722–1760.</Citation><ArticleIdList><ArticleId IdType="pubmed">36471135</ArticleId><ArticleId IdType="pmc">9735008</ArticleId><ArticleId IdType="doi">10.1038/s41587-022-01582-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes, B., Castro, R., Bhoelan, F., Bemelman, D., Gomes, R. A., Costa, J., Gomes-Alves, P., Stegmann, T., Amacker, M., Alves, P. M., Fleury, S., Roldão, A. (2022). Insect cells for high-yield production of SARS-CoV-2 spike protein: Building a virosome-based COVID-19 vaccine candidate. Pharmaceutics, 14(4), 854.</Citation><ArticleIdList><ArticleId IdType="pubmed">35456687</ArticleId><ArticleId IdType="pmc">9031128</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics14040854</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, D., Baudys, J., Bundy, J. L., Solano, M., Keppel, T., &amp; Barr, J. R. (2020). Comprehensive analysis of the glycan complement of SARS-CoV-2 spike proteins using signature ions-triggered Electron-Transfer/Higher-Energy Collisional Dissociation (EThcD) mass spectrometry. Analytical Chemistry, 92(21), 14730–14739.</Citation><ArticleIdList><ArticleId IdType="pubmed">33064451</ArticleId><ArticleId IdType="pmc">7586457</ArticleId><ArticleId IdType="doi">10.1021/acs.analchem.0c03301</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiefer, A. M., Niemeyer, J., Probst, A., Erkel, G., &amp; Schroda, M. (2022). Production and secretion of functional SARS-CoV-2 spike protein in Chlamydomonas reinhardtii. Frontiers in Plant Science, 13, 988870.</Citation><ArticleIdList><ArticleId IdType="pubmed">36204065</ArticleId><ArticleId IdType="pmc">9530321</ArticleId><ArticleId IdType="doi">10.3389/fpls.2022.988870</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, T., Li, T., Chen, G., Zhu, Y., Xu, L., Lin, Y., Sun, H., Zhang, H., Fang, Q., Hong, J., Wu, D., Gao, S., Li, S., Wang, Y., Zhang, T., Chen, Y., Yuan, Q., Zheng, Q., Yu, H., … Gu, Y. (2022). Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation. Vaccine, 40(47), 6839–6848.</Citation></Reference><Reference><Citation>Böhm, E., Seyfried, B. K., Dockal, M., Graninger, M., Hasslacher, M., Neurath, M., Konetschny, C., Matthiessen, P., Mitterer, A., &amp; Scheiflinger, F. (2015). Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells. BMC Biotechnology, 15, 87.</Citation><ArticleIdList><ArticleId IdType="pubmed">26382581</ArticleId><ArticleId IdType="pmc">4574471</ArticleId><ArticleId IdType="doi">10.1186/s12896-015-0205-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Steger, K., Brady, J., Duskin, M., &amp; Donato, K. (2020). CHO versus HEK cell glycosylation. Technical Report. Maxcyte.</Citation></Reference><Reference><Citation>Blundell, P. A., Lu, D., Dell, A., Haslam, S., &amp; Pleass, R. J. (2020). Choice of host cell line is essential for the functional glycosylation of the Fc region of human IgG1 inhibitors of influenza B viruses. Journal of Immunology, 204(4), 1022–1034.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1901145</ArticleId></ArticleIdList></Reference><Reference><Citation>Johari, Y. B., Jaffé, S. R. P., Scarrott, J. M., Johnson, A. O., Mozzanino, T., Pohle, T. H., Maisuria, S., Bhayat-Cammack, A., Lambiase, G., Brown, A. J., Tee, K. L., Jackson, P. J., Wong, T. S., Dickman, M. J., Sargur, R. B., &amp; James, D. C. (2021). Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing. Biotechnology and Bioengineering, 118(2), 1013–1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">33128388</ArticleId><ArticleId IdType="doi">10.1002/bit.27615</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee, K. L., Jackson, P. J., Scarrott, J. M., Jaffe, S. R. P., Johnson, A. O., Johari, Y., Pohle, T. H., Mozzanino, T., Price, J., Grinham, J., Brown, A., Nicklin, M. J., James, D. C., Dickman, M. J., &amp; Wong, T. S. (2020). Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay. bioRxiv.</Citation></Reference><Reference><Citation>Kelley, B., Kiss, R., &amp; Laird, M. (2018). In B. Kiss, U. Gottschalk, &amp; M. Pohlscheidt (Eds.), New bioprocessing strategies: Development and manufacturing of recombinant antibodies and proteins (pp. 443–462). Springer.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/10_2018_59</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh, J. B., &amp; Ng, S. K. (2018). Impact of host cell line choice on glycan profile. Critical Reviews in Biotechnology, 38(6), 207–217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07388551.2017.1416577</ArticleId></ArticleIdList></Reference><Reference><Citation>Croset, A., Delafosse, L., Gaudry, J.-P., Arod, C., Glez, L., Losberger, C., Begue, D., Krstanovic, A., Robert, F., Vilbois, F., Chevalet, L., &amp; Antonsson, B. (2012). Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. Journal of Biotechnology, 161(3), 336–348.</Citation><ArticleIdList><ArticleId IdType="pubmed">22814405</ArticleId><ArticleId IdType="doi">10.1016/j.jbiotec.2012.06.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler, M., &amp; Spearman, M. (2014). The choice of mammalian cell host and possibilities for glycosylation engineering. Current Opinion in Biotechnology, 30, 107–112.</Citation><ArticleIdList><ArticleId IdType="pubmed">25005678</ArticleId><ArticleId IdType="doi">10.1016/j.copbio.2014.06.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingg, N., Zhang, P., Song, Z., &amp; Bardor, M. (2012). The sweet tooth of biopharmaceuticals: Importance of recombinant protein glycosylation analysis. Biotechnology Journal, 7(12), 1462–1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">22829536</ArticleId><ArticleId IdType="doi">10.1002/biot.201200078</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks, S. A. (2004). Appropriate glycosylation of recombinant proteins for human use. Molecular Biotechnology, 28(3), 241–255.</Citation><ArticleIdList><ArticleId IdType="pubmed">15542924</ArticleId><ArticleId IdType="doi">10.1385/MB:28:3:241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wurm, F. M. (2004). Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotechnology, 22(11), 1393–1398.</Citation><ArticleIdList><ArticleId IdType="pubmed">15529164</ArticleId><ArticleId IdType="doi">10.1038/nbt1026</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. Y., Kim, Y.-G., &amp; Lee, G. M. (2012). CHO cells in biotechnology for production of recombinant proteins: Current state and further potential. Applied Microbiology and Biotechnology, 93, 917–930.</Citation><ArticleIdList><ArticleId IdType="pubmed">22159888</ArticleId><ArticleId IdType="doi">10.1007/s00253-011-3758-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpuche-Lazcano, S. P., Stuible, M., Akache, B., Tran, A., Kelly, J., Hrapovic, S., Robotham, A., Haqqani, A., Star, A., Renner, T. M., Blouin, J., Maltais, J.-S., Cass, B., Cui, K., Cho, J.-Y., Wang, X., Zoubchenok, D., Dudani, R., Duque, D., … Durocher, Y. (2023). Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells. Communications Medicine, 3(1), 116.</Citation></Reference><Reference><Citation>Fernandez-Martell, A., Johari, Y. B., &amp; James, D. C. (2018). Metabolic phenotyping of CHO cells varying in cellular biomass accumulation and maintenance during fed-batch culture. Biotechnology and Bioengineering, 115(3), 645–660.</Citation><ArticleIdList><ArticleId IdType="pubmed">29080362</ArticleId><ArticleId IdType="doi">10.1002/bit.26485</ArticleId></ArticleIdList></Reference><Reference><Citation>Millán-Martín, S., Jakes, C., Carillo, S., &amp; Bones, J. (2023). Multi-Attribute Method (MAM) analytical workflow for biotherapeutic protein characterization from process development to QC. Current Protocols, 3(11), 927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpz1.927</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, J., Hou, S., An, J., &amp; Zhou, C. (2023). In-depth characterization of protein N-glycosylation for a COVID-19 variant-design vaccine spike protein. Analytical and Bioanalytical Chemistry, 415(8), 1455–1464.</Citation><ArticleIdList><ArticleId IdType="pubmed">36698045</ArticleId><ArticleId IdType="pmc">9878482</ArticleId><ArticleId IdType="doi">10.1007/s00216-023-04533-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q., Wang, Y., Yang, S., Lin, C., Aliyu, L., Chen, Y., Parsons, L., Tian, Y., Jia, H., Pekosz, A., Betenbaugh, M. J., &amp; Cipollo, J. F. (2021). A linkage-specific sialic acid Labeling strategy reveals different site-specific glycosylation patterns in SARS-CoV-2 spike protein produced in CHO and HEK cell substrates. Frontiers in Chemistry, 9, 735558.</Citation><ArticleIdList><ArticleId IdType="pubmed">34631661</ArticleId><ArticleId IdType="pmc">8497748</ArticleId><ArticleId IdType="doi">10.3389/fchem.2021.735558</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C., Tan, Z., Zhao, K., Zou, W., Wang, H., Gao, H., Sun, S., Bu, D., Chai, W., &amp; Li, Y. (2021). The effect of N-glycosylation of SARS-CoV-2 spike protein on the virus interaction with the host cell ACE2 receptor. iScience, 24(11), 103272.</Citation><ArticleIdList><ArticleId IdType="pubmed">34661088</ArticleId><ArticleId IdType="pmc">8513389</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2021.103272</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira, R.-C., Grant, O. C., Moyo, T., Dorfman, J. R., Woods, R. J., Travers, S. A., &amp; Wood, N. T. (2018). Structural rearrangements maintain the glycan shield of an HIV-1 envelope trimer after the loss of a glycan. Scientific Reports, 8(1), 15031.</Citation><ArticleIdList><ArticleId IdType="pubmed">30302011</ArticleId><ArticleId IdType="pmc">6177452</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-33390-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Varki, A., Cummings, R. D., Aebi, M., Packer, N. H., Seeberger, P. H., Esko, J. D., Stanley, P., Hart, G., Darvill, A., Kinoshita, T., Prestegard, J. J., Schnaar, R. L., Freeze, H. H., Marth, J. D., Bertozzi, C. R., Etzler, M. E., Frank, M., Vliegenthart, J. F., Lütteke, T., … Kornfeld, S. (2015). Symbol nomenclature for graphical representations of glycans. Glycobiology, 25(12), 1323–1324.</Citation></Reference><Reference><Citation>Zhang, Y., Zhao, W., Mao, Y., Chen, Y., Wang, S., Zhong, Y., Su, T., Gong, M., Du, D., Lu, X., Cheng, J., &amp; Yang, H. (2021). Site-specific N-glycosylation characterization of recombinant SARS-CoV-2 spike proteins. Molecular and Cellular Proteomics, 20(100058), 1013–1021.</Citation></Reference><Reference><Citation>Shajahan, A., Supekar, N. T., Gleinich, A. S., &amp; Azadi, P. (2020). Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology, 30(12), 981–988.</Citation><ArticleIdList><ArticleId IdType="pubmed">32363391</ArticleId><ArticleId IdType="pmc">7239183</ArticleId><ArticleId IdType="doi">10.1093/glycob/cwaa042</ArticleId></ArticleIdList></Reference><Reference><Citation>Yehuda, S., &amp; Padler-Karavani, V. (2020). Glycosylated biotherapeutics: Immunological effects of N-glycolylneuraminic acid. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.00021</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00021</ArticleId><ArticleId IdType="pubmed">32038661</ArticleId><ArticleId IdType="pmc">6989436</ArticleId></ArticleIdList></Reference><Reference><Citation>Fliedl, L., Grillari, J., &amp; Grillari-Voglauer, R. (2015). Human cell lines for the production of recombinant proteins: On the horizon. New Biotechnology, 32(6), 673–679.</Citation><ArticleIdList><ArticleId IdType="pubmed">25529337</ArticleId><ArticleId IdType="doi">10.1016/j.nbt.2014.11.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaderi, D., Zhang, M., Hurtado-Ziola, N., &amp; Varki, A. (2012). Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnology and Genetic Engineering Reviews, 28(1), 147–176.</Citation><ArticleIdList><ArticleId IdType="pubmed">22616486</ArticleId><ArticleId IdType="doi">10.5661/bger-28-147</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., &amp; Varki, A. (2010). Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nature Biotechnology, 28(8), 863–867.</Citation><ArticleIdList><ArticleId IdType="pubmed">20657583</ArticleId><ArticleId IdType="pmc">3077421</ArticleId><ArticleId IdType="doi">10.1038/nbt.1651</ArticleId></ArticleIdList></Reference><Reference><Citation>Angata, T., &amp; Varki, A. (2002). Chemical diversity in the sialic acids and related α-keto acids: An evolutionary perspective. Chemical Reviews, 102(2), 439–470.</Citation><ArticleIdList><ArticleId IdType="pubmed">11841250</ArticleId><ArticleId IdType="doi">10.1021/cr000407m</ArticleId></ArticleIdList></Reference><Reference><Citation>Varki, A. (2001). Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution. American Journal of Biological Anthropology, 116(S33), 54–69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajpa.10018</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardor, M., Nguyen, D. H., Diaz, S., &amp; Varki, A. (2005). Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. Journal of Biological Chemistry, 280(6), 4228–4237.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557321</ArticleId><ArticleId IdType="doi">10.1074/jbc.M412040200</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda, K., Gregg, C. J., Chow, R., Varki, N. M., &amp; Varki, A. (2012). Metabolism of vertebrate amino sugars with N-glycolyl groups: Mechanisms underlying gastrointestinal incorporation of the non-human sialic acid xeno-autoantigen N-glycolylneuraminic acid. Journal of Biological Chemistry, 287(34), 28852–28864.</Citation><ArticleIdList><ArticleId IdType="pubmed">22692204</ArticleId><ArticleId IdType="pmc">3436511</ArticleId><ArticleId IdType="doi">10.1074/jbc.M112.364182</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., &amp; Muchmore, E. (2003). Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proceedings of the National Academy of Sciences of USA, 100(21), 12045–12050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2131556100</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, D. H., Tangvoranuntakul, P., &amp; Varki, A. (2005). Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. Journal of Immunology, 175(1), 228–236.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.1.228</ArticleId></ArticleIdList></Reference><Reference><Citation>Okerblom, J., &amp; Varki, A. (2017). Biochemical, cellular, physiological, and pathological consequences of human loss of N-Glycolylneuraminic acid. ChemBioChem, 18(13), 1155–1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">28423240</ArticleId><ArticleId IdType="doi">10.1002/cbic.201700077</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, A., &amp; Hurst, R. (2002). Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation, 9(6), 376–381.</Citation><ArticleIdList><ArticleId IdType="pubmed">12371933</ArticleId><ArticleId IdType="doi">10.1034/j.1399-3089.2002.02138.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Padler-Karavani, V., Yu, H., Cao, H., Chokhawala, H., Karp, F., Varki, N., Chen, X., &amp; Varki, A. (2008). Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. Glycobiology, 18(10), 818–830.</Citation><ArticleIdList><ArticleId IdType="pubmed">18669916</ArticleId><ArticleId IdType="pmc">2586336</ArticleId><ArticleId IdType="doi">10.1093/glycob/cwn072</ArticleId></ArticleIdList></Reference><Reference><Citation>Leviatan Ben-Arye, S., Yu, H., Chen, X., &amp; Padler-Karavani, V. (2017). Profiling anti-Neu5Gc IgG in human sera with a sialoglycan microarray assay. Journal of Visualized Experiments. https://doi.org/10.3791/56094</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/56094</ArticleId><ArticleId IdType="pubmed">28745644</ArticleId><ArticleId IdType="pmc">5612302</ArticleId></ArticleIdList></Reference><Reference><Citation>Padler-Karavani, V., Hurtado-Ziola, N., Pu, M., Yu, H., Huang, S., Muthana, S., Chokhawala, H. A., Cao, H., Secrest, P., Friedmann-Morvinski, D., Singer, O., Ghaderi, D., Verma, I. M., Liu, Y.-T., Messer, K., Chen, X., Varki, A., &amp; Schwab, R. (2011). Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Research, 71(9), 3352–3363.</Citation><ArticleIdList><ArticleId IdType="pubmed">21505105</ArticleId><ArticleId IdType="pmc">3085609</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-10-4102</ArticleId></ArticleIdList></Reference><Reference><Citation>Leviatan Ben-Arye, S., Schneider, C., Yu, H., Bashir, S., Chen, X., Gunten, S., &amp; Padler-Karavani, V. (2019). Differential recognition of diet-derived Neu5Gc-neoantigens on glycan microarrays by carbohydrate-specific pooled human IgG and IgA antibodies. Bioconjugate Chemistry, 30(5), 1565–1574.</Citation><ArticleIdList><ArticleId IdType="pubmed">30994337</ArticleId><ArticleId IdType="pmc">6756923</ArticleId><ArticleId IdType="doi">10.1021/acs.bioconjchem.9b00273</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, Q., Padler-Karavani, V., Yu, H., Chen, X., Wu, S.-L., Varki, A., &amp; Hancock, W. S. (2012). LC–MS analysis of polyclonal human anti-Neu5Gc xeno-autoantibodies immunoglobulin G Subclass and partial sequence using multistep intravenous immunoglobulin affinity purification and multienzymatic digestion. Analytical Chemistry, 84(6), 2761–2768.</Citation><ArticleIdList><ArticleId IdType="pubmed">22390546</ArticleId><ArticleId IdType="pmc">4142218</ArticleId><ArticleId IdType="doi">10.1021/ac2030893</ArticleId></ArticleIdList></Reference><Reference><Citation>Samraj, A. N., Läubli, H., Varki, N., &amp; Varki, A. (2014). Involvement of a non-human sialic acid in human cancer. Frontiers in Oncology, 4, 33.</Citation><ArticleIdList><ArticleId IdType="pubmed">24600589</ArticleId><ArticleId IdType="pmc">3928833</ArticleId></ArticleIdList></Reference><Reference><Citation>Malykh, Y. N., Schauer, R., &amp; Shaw, L. (2001). N-Glycolylneuraminic acid in human tumours. Biochimie, 83(7), 623–634.</Citation><ArticleIdList><ArticleId IdType="pubmed">11522391</ArticleId><ArticleId IdType="doi">10.1016/S0300-9084(01)01303-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Samraj, A. N., Pearce, O. M., Läubli, H., Crittenden, A. N., Bergfeld, A. K., Banda, K., Gregg, C. J., Bingman, A. E., Secrest, P., Diaz, S. L., Varki, N. M., &amp; Varki, A. (2015). A red meat-derived glycan promotes inflammation and cancer progression. Proceedings of the National Academy of Sciences of USA, 112(2), 542–547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1417508112</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar, C., Sasmal, A., &amp; Varki, A. (2019). From “serum sickness’’ to “xenosialitis’’: Past, present, and future significance of the non-human sialic acid Neu5Gc. Frontiers in Immunology, 10, 807.</Citation><ArticleIdList><ArticleId IdType="pubmed">31057542</ArticleId><ArticleId IdType="pmc">6481270</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.00807</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham, T., Gregg, C. J., Karp, F., Chow, R., Padler-Karavani, V., Cao, H., Chen, X., Witztum, J. L., Varki, N. M., &amp; Varki, A. (2009). Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. Blood, 114(25), 5225–5235.</Citation><ArticleIdList><ArticleId IdType="pubmed">19828701</ArticleId><ArticleId IdType="pmc">2792214</ArticleId><ArticleId IdType="doi">10.1182/blood-2009-05-220400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>